OSLO, Norway (12 February 2026) - TGS today reports interim financial results for Q4 2025. Financial highlights: Q4 Revenues of USD 363 million, driven by strong multi-client performance (sales-to-investment of 2.0x for the full year 2025) Solid order inflow of USD 598 million in Q4 2025 - total order backlog increased to USD 706 million Net cash flow of USD 206 million in 2025 Improved balance sheet resilience by reducing net debt by USD 73 million in 2025, to USD 427 million Stable dividend payment of USD 0.155 per share to be paid in Q1 2026 2026 guidance: Multi-client investment in the range of USD 500-575 million supported by strong customer commitments, up from USD 447 million in 2025 Significant increase in vessel utilization driven by high multi-client activity - OBN activity expected to be in-line with 2025 Gross operating cost of approximately USD 950 million – Capex at approximately the same level as in 2025. “Considering the difficult market conditions, I am satisfied with our Q4 2025 results. We gained significant traction with customers, achieving an order inflow of USD 598 million — our best quarter since before the pandemic. Our multi-client business performed well, and strong momentum at year-end meant our sales-to-investment ratio met our annual goal of 2.0x. Although contract revenues in Marine Data Acquisition were affected by reduced proprietary seismic survey activity, our integrated business model allowed us to improve asset utilization, thanks to increased demand for multi-client projects. The Imaging division benefited from a sharpened strategic approach, producing a 65% growth in pro-forma external revenue for 2025. Throughout the year, we maintained our focus on cost and capital efficiency, which led to a substantial reduction in costs. Consequently, we generated a net cash flow before dividends of more than USD 200 million and lowered net debt to USD 427 million by year-end, despite revenue declines and challenging market conditions. Due ...

Croissance des ventes totales du Groupe en 2025 de 10,9% à taux de change constant 1 (8,1% en données publiées), tirée par la croissance des trois aires thérapeutiques avec une croissance de 4,1% 1 en Oncologie, 102,5% 1 dans les Maladies Rares et 9,7% 1 en Neurosciences. Croissance des ventes de Somatuline® de 4,3% 1 , tandis que le portefeuille de médicaments hors Somatuline, affiche une croissance à deux chiffres de 14,2% 1 (8,1% en données publiées), tirée par la croissance des trois aires thérapeutiques avec une croissance de 4,1% en Oncologie, 102,5% dans les Maladies Rares et 9,7% en Neurosciences. Croissance des ventes de Somatuline® de 4,3% , tandis que le portefeuille de médicaments hors Somatuline, affiche une croissance à deux chiffres de 14,2% Résultat opérationnel des activités 2025 de 1 294 millions d'euros, en hausse de 16,7% en données publiées, représentant une marge opérationnelle des activités de 35,2% des ventes totales, en hausse de 2,6 points Poursuite de l’expansion du portefeuille de médicaments en 2025, portée par d’importantes avancées réglementaires et cliniques, l’intégration de multiples actifs précliniques assortis de droits mondiaux et fondés sur des approches innovantes, ainsi que l’ajout d’un actif en phase de développement clinique intermédiaire issu de l’acquisition d’ImCheck Therapeutics Cinq étapes réglementaires et cliniques majeures attendues en 2026, auxquelles s’ajoute la présentation complète des données d’IPN10200 dans une indication esthétique Objectifs financiers2 pour l’année 2026, avec une croissance des ventes totales du Groupe supérieure à 13,0%3 à taux de change constant, compte tenu d’une accélération du portefeuille hors Somatuline et une croissance de Somatuline liée aux difficultés de production de génériques du lanréotide, et une marge opérationnelle des activités supérieure à 35,0%. PARIS, FRANCE, 12 février 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de spécialité, présente a...

FY 2025 sales growth of 10.9% at CER 1 , or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1% 1 ), Rare Disease (102.5% 1 ) and Neuroscience (9.7% 1 ); Somatuline® sales growth of 4.3% 1 , with all other products, excluding Somatuline, achieving double-digit sales growth of 14.2% 1 , or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1% ), Rare Disease (102.5% ) and Neuroscience (9.7% ); Somatuline® sales growth of 4.3% , with all other products, excluding Somatuline, achieving double-digit sales growth of 14.2% FY 2025 core operating income of €1,294m, growing by 16.7% as reported, with a core operating margin of 35.2% of total sales, increasing by 2.6 points 2025 continued pipeline expansion, driven by significant regulatory and clinical milestones, integration of multiple preclinical assets with global rights and innovative approaches, and a mid-stage candidate from the acquisition of ImCheck Therapeutics Five major regulatory and clinical milestones expected in 2026, in addition to the full data readout for IPN10200 in an aesthetics indication Financial guidance2 for 2026 including total sales growth greater than 13.0%3 at CER, assuming an acceleration of our portfolio excluding Somatuline as well as the growth of Somatuline due to generic lanreotide production challenges, and core operating margin greater than 35.0% of total sales PARIS, FRANCE, 12 February 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year (FY) 2025 and for the fourth quarter of 2025. Extract of consolidated results4 for FY25 and FY24 FY 2025 FY 2024 % change €m €m Actual CER Total Sales 3,675.9 3,400.6 8.1 % 10.9 % Core Operating Income 1,294.1 1,109.4 16.7 % Core operating margin 35.2 % 32.6 % +2.6pts Core Consolidated Net Profit 1,009.1 857.8 17.6 % Core earnings per share (fully diluted) €12.09 €10.27 17.8 % IFRS Operating Incom...

Regulated information Challenging 2025, with results in line with latest outlook, but significantly lower than initial expectations; Clear priorities set for 2026 to resume profit growth and improve cash generation, and strategic review initiated Full year results in line with latest reviewed outlook: Revenue decreased by 4.9% LFL and adj. EBITDA margin by 2pp to 10%, on soft demand for baby care retailer brands and supply chain constraints; Net debt reduced by 6%, despite negative FCF, thanks to net proceeds from the completion of the Emerging Markets divestments, while leverage increased to 3.3x on lower adj. EBITDA; Recent challenges being addressed with clear priorities set for 2026 to resume volume growth, extend the cost transformation program, as well as laser focus on cash; Targeting adj. EBITDA growth of 10% in 2026, albeit gradually improving throughout the year from soft Q1, thereby leading to positive FCF and leverage to drop to 3x or lower by year end; Strategic review initiated to unlock additional value creation. CEO quote Laurent Nielly, Ontex’s CEO, said: “I am honored by the Board’s trust to lead the company in this difficult moment. Our performance in 2025 has clearly not met expectations. While we continued to make progress to transform the business, the pace was not enough to compensate for the market unexpected demand drop and our own execution challenges. While we have started a review of the strategy, we are focusing on the execution of our existing plans with stronger financial discipline. We aim to resume adjusted EBITDA growth, while continuing to find additional fuel to reestablish the baseline for sustained growth as the year progresses. We have strong assets and people, and I am convinced that the work started will allow us to unlock Ontex’s intrinsic value.” FY 2025 results summary Revenue was €1,762 million, a ‑4.9% like-for-like decrease, entirely linked to lower volumes, with improving product mix offsetting limited targeted price d...

Press Release Kaiseraugst (Switzerland), Maastricht (Netherlands), February 12, 2026 dsm-firmenich reports full year 2025 results Management Report 2025 highlights Good financial performance, with strong contribution from synergies Strategic plan now fully executed following the announced divestment of Animal Nutrition & Health Animal Nutrition & Health has been classified as Assets Held for Sale and Discontinued Operations New €500 million share repurchase program to be launched in Q1 2026 Maintain stable dividend of €2.50 per share, adopting stable to preferably rising dividend policy Good progress in Sustainability, including EcoVadis Platinum and CDP double A for Climate & Water dsm-firmenich now ready for the next phase in its journey as a fully focused consumer company Investor Event scheduled for March 12, 2026 Key figures - Continuing Operations1 in € millions FY 2025 FY 2024 % Change Q4 2025 Q4 2024 % Change Sales 9,034 9,054 (0) 2,153 2,239 (4) Organic sales growth (%) 3 2 Adj. EBITDA 1,772 1,751 1 408 424 (4) Adj. EBITDA margin (%) 19.6 19.3 19.0 18.9 Net profit from continuing operations 342 359 Key figures - Total Group including Discontinued Operations1 in € millions 2025 2024 % Change Sales 12,521 12,799 (2) Adjusted EBITDA 2,279 2,118 8 Net profit (1,039) 280 1 Continuing Operations reflects the results of dsm-firmenich, following the announced divestment of Animal Nutrition & Health (ANH) activities to CVC Capital Partners. The assets and liabilities of the divested businesses have been classified as Assets Held for Sale in accordance with IFRS 5, and the results of the divested businesses have been reclassified to Discontinued Operations. Dimitri de Vreeze, CEO, commented: “The recently announced divestment of Animal Nutrition & Health marks the final step in executing our strategic roadmap to becoming a leading consumer-focused company in nutrition, health, and beauty. This is an important milestone for the company. It enables us to fully focus on...

Savings Banks Group's Release of Financial Statements for 2025 has been published.

Sp Mortgage Bank Plc Stock Exchange Release 12th February 2026 at 8 am (CET +1) Savings Banks Group's Release of Financial Statements for 2025 has been published. Document containing the Financial Statements Release is attached to this release. The Financial Statements Release can be also found at www.saastopankki.fi. SAVINGS BANKS GROUP Additional information: Kai Koskela, CEO Savings Banks' Union Coop kai.koskela@sastopankki.fi +358 40 549 0430 Attachment

Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 12 februari 2026 – 7:00 AM CET Fagron behoudt uitstekende prestaties in boekjaar 2025 met 9,2% omzetgroei en een stijging van de REBITDA met 10,9% Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, publiceert vandaag haar jaarresultaten voor de periode eindigend op 31 december 2025. Belangrijkste hoogtepunten Sterke omzetgroei met een gerapporteerde stijging van 9,2% (12,9% tegen CER 1 ) tot €952,2 miljoen, boven de verwachtingen en ondersteund door alle regio’s en segmenten Organische groei tegen CER van 9,1%, wat de aanhoudende onderliggende vraag en gedisciplineerde commerciële uitvoering weerspiegelt Verbeterde winstgevendheid met een stijging van REBITDA met 10,9% op jaarbasis tot €192,9 miljoen, en een REBITDA ‑ marge van 20,3%, gesteund door operating leverage en initiatieven op het gebied van operationele efficiëntie Sterke kasgeneratie met een operationele kasstroom van €155,3 miljoen en een vrije kasstroom van €125,9 miljoen 2 (+29,0% op jaarbasis) Daling van de leverage ratio naar 1,2x (2024: 1,4x), wat ruime financieringscapaciteit biedt voor geplande uitbreidingsinvesteringen en getekende overnames Aanhoudende M&A ‑ dynamiek, met 12 aangekondigde overnames in alle regio’s en segmenten; integratie van afgeronde overnames verloopt volgens plan WPA van €1,25 (+13,6% op jaarbasis), met een CAGR van 9% over de afgelopen 8 jaar (2017: €0,65). Voorstel voor een dividend van €0,40 per aandeel (+14,3% op jaarbasis) Vooruitzichten 2026: organische omzetgroei van mid‑ tot high-single digit en een licht verbeterende marge op jaarbasis Rafael Padilla, CEO van Fagron: “Ik ben buitengewoon tevreden met de resultaten die we in 2025 hebben geleverd. De groei was breed gedragen over regio’s en segmenten, ondersteund door ons gediversifieerde model, gedisciplineerde commerciële uitvoering en voortdurende vooruitgang op het gebied van operationele efficiëntie. De productbeschikbaa...

Central Bank of Savings Banks Finland Plc Stock Exchange Release 12th February 2026 at 8 am (CET +1) Savings Banks Group's Release of Financial Statements for 2025 has been published. Document containing the Financial Statements Release is attached to this release. The Financial Statements Release can be also found at www.saastopankki.fi. SAVINGS BANKS GROUP Additional information: Kai Koskela, CEO Savings Banks' Union Coop kai.koskela@sastopankki.fi +358 40 549 0430 Attachment

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2025. Key Highlights Strong revenue growth with 9.2% reported growth (12.9% at CER 1 ) to reach €952.2 million , ahead of guidance and supported by all regions and segments Organic growth at CER of 9.1% reflecting continued underlying demand and disciplined commercial execution Profitability increased with REBITDA up 10.9% YoY to €192.9 million, and REBITDA margin of 20.3%, supported by operating leverage and operational excellence initiatives Solid cash generation with operating cash flow of €155.3 million, and free cash flow of €125.9 million 2 (+29.0% YoY) Leverage ratio decreased to 1.2x (2024: 1.4x), offering ample headroom to fund our expansion capex projects and signed acquisitions Continued M&A momentum with 12 acquisitions announced across all regions and segments this year; integration of closed acquisitions progressing as planned EPS of €1.25 (+13.6% YoY), with a 9% CAGR over the last 8 years (2017: €0.65). Dividend proposal of €0.40 per share (+14.3% YoY) FY 2026 outlook: mid- to high-single digit organic sales growth and margin slightly improving YoY Rafael Padilla, CEO of Fagron: “I am incredibly pleased with the performance we delivered in 2025. Growth was broad-based across regions and segments, supported by our diversified model, disciplined commercial execution and continued progress on operational excellence. Product availability across the Group was above 90%, while procurement and manufacturing savings were also ahead of target. In EMEA, we delivered a resilient performance, supported by geographical diversification and the integration of recent acquisitions. Latin America maintained strong momentum, partic...

Central Bank of Savings Banks Finland Plc's IFRS financial statements and Board of Directors' report for 2025 have been published. Stock Exchange Release12th of February 2026 at 8 am (CET +1) The...

Gereglementeerde informatie Uitdagend 2025, met resultaten in lijn met de laatste vooruitzichten, maar significant onder de initiële verwachtingen; Duidelijke prioriteiten voor 2026 om winstgroei te hervatten en kasgeneratie te verbeteren, en strategische evaluatie in gang gezet Jaarresultaten in lijn met laatste herziene vooruitzichten: De omzet daalde met 4,9% LFL en de aangepaste EBITDA-marge met 2 procentpunten tot 10%, door de zwakke vraag naar retailermerken in babyverzorging en verstoringen in de toeleveringsketen; De nettoschuld daalde met 6%, ondanks de negatieve vrije kasstroom, dankzij de netto-opbrengsten volgend op de desinvestering van Emerging Markets, terwijl de hefboomratio steeg tot 3.3x door de lagere aangepaste EBITDA; Recente uitdagingen worden aangepakt en duidelijke prioriteiten gezet voor 2026 om de volumegroei te hervatten, het kostentransformatieprogramma uit te breiden en sterk te focussen op kasgeneratie; Aangepaste EBITDA groei van 10% beoogd in 2026, zij het met geleidelijke verbetering over het jaar startend van een zwakker eerste kwartaal, wat leidt tot positieve vrije kasstroom en een daling van de hefboomratio tot 3x of minder tegen jaareinde. Strategische evaluatie gestart om extra waardecreatie te ontsluiten. CEO-citaat Laurent Nielly, CEO van Ontex, zei: "Ik voel me vereerd door het vertrouwen dat de raad van bestuur in mij stelt om het bedrijf in dit moeilijke moment te leiden. Onze prestaties in 2025 hebben de verwachtingen duidelijk niet ingelost. Hoewel we vooruitgang bleven boeken in de transformatie van het bedrijf, was het tempo onvoldoende om de onverwachte vraagdaling in de markt en onze eigen uitvoeringsproblemen te compenseren. Terwijl we een herziening van de strategie zijn gestart, richten we ons op de uitvoering van onze bestaande plannen met een sterkere financiële discipline. We streven ernaar de groei van de aangepaste EBITDA te hervatten, terwijl we blijven zoeken naar extra middelen om de basis voor duurzame gr...

HIAB CORPORATION, FINANCIAL STATEMENTS REVIEW 2025, 12 FEBRUARY 2026 AT 8:00 AM (EET) Hiab's financial statements review 2025: Comparable operating profit margin continued to improve in 2025 Highlights of 2025 Market environment was characterised by increased trade tensions and uncertainties Orders received remained at past two years’ level and amounted to EUR 1,481 (1,509) million Record high full year comparable operating profit margin of 13.7 (13.2) percent, despite 6 percent lower sales Record year in Services Strong cash generation continued, cash flow from operations before finance items and taxes totalled EUR 308 (582) million Hiab complemented its portfolio in Brazil with the acquisition of ING Cranes The figures in this financial statements review are based on Hiab Corporation’s audited 2025 financial statements. Unless otherwise stated, the financial information in this report concerns Hiab's continuing operations. October–December 2025 in brief: Operating profit increased Orders received decreased by 9 percent and totalled EUR 375 (414) million. Organically in constant currencies orders decreased by 6 percent. Order book amounted to EUR 534 (31 Dec 2024: 648) million at the end of the period. Sales decreased by 4 percent and totalled EUR 396 (412) million, unchanged organically in constant currencies. Equipment sales represented 71 (71) and Services sales represented 29 (29) percent of sales. Eco portfolio sales 1 increased by 11 percent and totalled EUR 135 (122) million, representing 34 (30) percent of sales. increased by 11 percent and totalled EUR 135 (122) million, representing 34 (30) percent of sales. EBITA was EUR 43 (42) million, representing 10.8 (10.1) percent of sales. Operating profit was EUR 42 (41) million, representing 10.6 (9.9) percent of sales. Comparable operating profit increased by 15 percent and amounted to EUR 47 (41) million, representing 11.9 (9.9) percent of sales. Profit for the period amounted to EUR 33 (27) million. Basic ear...

Marimekko Corporation, Financial Statements Bulletin, 12 February 2026 at 8.00 a.m. EET MARIMEKKO FINANCIAL STATEMENTS BULLETIN 2025: Marimekko’s net sales in the fourth quarter grew from the comparison period’s record level and operating profit margin was at a good level despite the continued challenging market situation This release is a summary of Marimekko’s financial statements bulletin for the January-December period of 2025. The complete report is attached to this release as a pdf file and it is also available on the company’s website at company.marimekko.com under Releases & publications. The fourth quarter in brief Marimekko’s net sales increased by 1 percent and totaled EUR 54.7 million (54.0). Net sales were boosted in particular by increased retail and wholesale sales in the Asia-Pacific region. Retail sales also grew in all other international market areas. In total, international sales increased by 5 percent. Net sales in Finland were down by 1 percent as retail sales decreased. Domestic wholesale sales were increased by non-recurring promotional deliveries, which in the comparable year were strongly weighted in the first half of the year. Operating profit amounted to EUR 8.7 million (9.1) and comparable operating profit totaled EUR 8.8 million (9.3) equaling to 16.1 percent of net sales (17.1). Operating profit was decreased by higher fixed costs. On the other hand, improved relative sales margin and increased net sales had a positive impact on operating profit. Year 2025 in brief The company’s net sales grew by 4 percent and totaled EUR 189.6 million (182.6). Net sales were boosted especially by the growth of wholesale sales in the Asia-Pacific region and Europe as well as increased retail sales in Scandinavia. As previously estimated, net sales were weakened by licensing income being considerably below the strong comparable year. Net sales in Finland increased by 1 percent due to, in particular, the positive development of licensing income. Internat...

HIAB CORPORATION, PRESS RELEASE, 11 FEBRUARY 2026 AT 2:30 PM (EET) Hiab appoints Custom Truck One Source as new dealer to secure strategic growth in the Western and Northeastern US Hiab, a leading...

Marimekko Oyj, Tilinpäätöstiedote 12.2.2026 klo 8.00 MARIMEKON TILINPÄÄTÖSTIEDOTE 2025: Marimekon liikevaihto neljännellä neljänneksellä nousi vertailukauden ennätystasolta ja liikevoittomarginaali oli hyvä haastavana jatkuneesta markkinatilanteesta huolimatta Tämä tiedote on tiivistelmä Marimekon tammi-joulukuun 2025 tilinpäätöstiedotteesta. Tilinpäätöstiedote kokonaisuudessaan on tämän tiedotteen liitteenä pdf-tiedostona, ja se on saatavilla myös yhtiön kotisivuilla company.marimekko.com kohdassa Tiedotteet ja julkaisut. Neljäs vuosineljännes lyhyesti Marimekon liikevaihto kasvoi 1 prosentin ja oli 54,7 miljoonaa euroa (54,0). Liikevaihtoa nosti erityisesti vähittäis- ja tukkumyynnin kasvu Aasian-Tyynenmeren alueella. Vähittäismyynti kasvoi myös kaikilla muilla kansainvälisillä markkina-alueilla. Yhteensä kansainvälinen liikevaihto kasvoi 5 prosenttia. Liikevaihto Suomessa jäi 1 prosentin vertailukaudesta vähittäismyynnin laskiessa. Tukkumyyntiä nostivat kotimaan kertaluonteiset kampanjatoimitukset, jotka vertailuvuonna painottuivat voimakkaasti vuoden ensimmäiselle puoliskolle. Liikevoitto oli 8,7 miljoonaa euroa (9,1) ja vertailukelpoinen liikevoitto 8,8 miljoonaa euroa (9,3) eli 16,1 prosenttia liikevaihdosta (17,1). Liikevoittoa heikensivät korkeammat kiinteät kustannukset. Suhteellisen myyntikatteen paraneminen ja liikevaihdon nousu puolestaan tukivat liikevoittoa. Vuosi 2025 lyhyesti Yhtiön liikevaihto kasvoi 4 prosenttia ja oli 189,6 miljoonaa euroa (182,6). Liikevaihtoa nostivat erityisesti tukkumyynnin kasvu Aasian-Tyynenmeren alueella ja Euroopassa sekä vähittäismyynnin nousu Skandinaviassa. Liikevaihtoa puolestaan heikensi aiemmin arvioidun mukaisesti lisenssituottojen jääminen merkittävästi vahvasta vertailuvuodesta. Liikevaihto Suomessa kasvoi 1 prosentin erityisesti lisenssituottojen myönteisen kehityksen ansiosta. Kansainvälinen liikevaihto nousi 7 prosenttia, kun sekä vähittäis- että tukkumyynti kasvoivat. Liikevoitto nousi 31,8 miljoonaan euroon (...

騰訊控股(00700)出現大手買入2.87萬股，成交價$535.0，涉資1.535千萬 AASTOCKS.com

中芯國際(00981)出現大手買入8.3萬股，成交價$70.3，涉資583.49萬 AASTOCKS.com

騰訊控股(00700)出現大手買入2萬股，成交價$535.0，涉資1.07千萬 AASTOCKS.com

0P0000NRGW.IR 認購資訊 | Pensjonsprofil I 50股份的投資資訊 Yahoo 財經

格隆汇2月12日丨贝伦贝格将诺和诺德目标价从415丹麦克朗下调至360丹麦克朗。

蓮華資本管理合夥人洪灝認為，美元進入貶值周期，有利中國股幣上升，預料離岸人民幣升至6.8水平，恒指今年目標30,000點。

蓮華資本管理合夥人洪灝認為，美元進入貶值周期，有利中國股幣上升，預料離岸人民幣升至6.8水平，恒指今年目標30,000點。

(RTTNews) - Isuzu Motors Ltd. (ISUZY.PK, 7202.T) reported Thursday lower profit in the first nine months of fiscal year 2026, despite higher revenues. Further, the firm maintained full-year profit and revenue forecast. In Tokyo, the shares were gaining 1.8 percent, trading at 2,804.00 yen. For the nine-month period, profit attributable to owners of parent was 121.21 billion yen, down 1.1 percent from 122.58 billion yen in the same period a year ago. Earnings per share, however, grew to 172.59 yen from 165.51 yen last year. Operating profit dropped 12.4 percent to 172.46 billion yen from 196.79 billion yen a year ago. Revenue, however, grew 5.3 percent to 2.51 trillion yen from 2.38 trillion yen in the previous year. Looking ahead for fiscal 2026, the company continues to expect profit attributable to owners of parent of 130.0 billion yen or 186.16 yen per share, down 7.2 percent year-over-year; operating profit of 210 billion yen, down 8.5 percent from last year, and revenue of 3.30 trillion yen, up 2 percent year-over-year. For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

据同花顺iFinD数据，沪深京三市成交额超1.7万亿元，较上日此时放量859亿元，预计全天成交金额约2.1万亿元。截至目前，沪市成交额7072亿元，深市成交额9790亿元，北证50成交额143亿元。

文章提及标的 天数智芯 -- 壁仞科技 -- 兆易创新 -- 天域半导体 -- 半导体 -- 上海复旦 -- 港股芯片股延续涨势，天数智芯（HK9903）午后涨幅扩大至25%，壁仞科技（HK6082）涨近10%，兆易创新（HK3986）涨超8%，天域半导体（HK2658）、上海复旦（HK1385）涨超5%。

Swissquote Broker Follow This content is written by Vincent Ganne for Swissquote. This content is intended for individuals who are familiar with financial markets and instruments and is for information purposes only and does not constitute investment, legal or tax advice.

美團－Ｗ(03690)出現大手買入9.36萬股，成交價$84.65，涉資792.324萬 AASTOCKS.com

格隆汇2月12日｜今日，金通灵科技集团股份有限公司（证券简称：*ST金灵，代码：300091）在完成资本公积金转增股本及除权后复牌交易。 根据公开信息，汇通达网络（9878.HK）作为金通灵本次重整引入的产业投资人，以1.3996元/股的价格受让7.1亿股转增股份。 金通灵今日开盘交投活跃，盘中股价一度大涨超16%，较汇通达投资成本形成显著估值空间，这一走势也反映出资本市场对金通灵重整前景的积极预期。

AI应用概念股震荡走高，利欧股份涨停 2026-02-12 13:56:37 来源： 同花顺7x24快讯 分享 文章提及标的 科远智慧 -- 利欧股份 -- 昆仑万维 -- 蓝色光标 -- 万兴科技 -- 光云科技 -- ai应用（886108）概念股震荡走高，利欧股份（002131）涨停，昆仑万维（300418）涨超10%，蓝色光标（300058）涨超5%，万兴科技（300624）、科远智慧（002380）、光云科技（688365）跟涨。